Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. More Details
Flawless balance sheet, good value and pays a dividend.
Share Price & News
How has Boiron's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BOI is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BOI's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: BOI exceeded the French Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: BOI exceeded the French Market which returned -3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Boiron's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StAre Boiron SA (EPA:BOI) Investors Paying Above The Intrinsic Value?
3 weeks ago | Simply Wall StCan Mixed Fundamentals Have A Negative Impact on Boiron SA (EPA:BOI) Current Share Price Momentum?
1 month ago | Simply Wall StBoiron SA (EPA:BOI) Is Yielding 2.5% - But Is It A Buy?
Is Boiron undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BOI (€38.8) is trading above our estimate of fair value (€29.14)
Significantly Below Fair Value: BOI is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BOI is good value based on its PE Ratio (17x) compared to the XE Pharmaceuticals industry average (23.1x).
PE vs Market: BOI is good value based on its PE Ratio (17x) compared to the French market (21.1x).
Price to Earnings Growth Ratio
PEG Ratio: BOI is good value based on its PEG Ratio (0.5x)
Price to Book Ratio
PB vs Industry: BOI is good value based on its PB Ratio (1.4x) compared to the FR Pharmaceuticals industry average (3.3x).
How is Boiron forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BOI's forecast earnings growth (31.7% per year) is above the savings rate (0.6%).
Earnings vs Market: BOI's earnings (31.7% per year) are forecast to grow faster than the French market (25.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BOI's revenue is expected to decline over the next 3 years (-1.9% per year).
High Growth Revenue: BOI's revenue is forecast to decline over the next 3 years (-1.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BOI's Return on Equity is forecast to be low in 3 years time (8.4%).
How has Boiron performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BOI has a large one-off loss of €35.7M impacting its June 30 2020 financial results.
Growing Profit Margin: BOI's current net profit margins (7.2%) are higher than last year (6.1%).
Past Earnings Growth Analysis
Earnings Trend: BOI's earnings have declined by 15.5% per year over the past 5 years.
Accelerating Growth: BOI's earnings growth over the past year (12.8%) exceeds its 5-year average (-15.5% per year).
Earnings vs Industry: BOI earnings growth over the past year (12.8%) underperformed the Pharmaceuticals industry 13.2%.
Return on Equity
High ROE: BOI's Return on Equity (8.3%) is considered low.
How is Boiron's financial position?
Financial Position Analysis
Short Term Liabilities: BOI's short term assets (€415.2M) exceed its short term liabilities (€183.2M).
Long Term Liabilities: BOI's short term assets (€415.2M) exceed its long term liabilities (€92.5M).
Debt to Equity History and Analysis
Debt Level: BOI's debt to equity ratio (1%) is considered satisfactory.
Reducing Debt: BOI's debt to equity ratio has reduced from 2.4% to 1% over the past 5 years.
Debt Coverage: BOI's debt is well covered by operating cash flow (1750.1%).
Interest Coverage: BOI earns more interest than it pays, so coverage of interest payments is not a concern.
What is Boiron current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BOI's dividend (2.71%) is higher than the bottom 25% of dividend payers in the French market (1.41%).
High Dividend: BOI's dividend (2.71%) is low compared to the top 25% of dividend payers in the French market (4.66%).
Stability and Growth of Payments
Stable Dividend: BOI's dividend payments have been volatile in the past 10 years.
Growing Dividend: BOI's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (45.9%), BOI's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BOI's dividends in 3 years are forecast to be well covered by earnings (42.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Valérie Lorentz-Poinsot (51 yo)
Ms. Valerie Lorentz-Poinsot serves as General Manager and Director of Development of Boiron SA and served as its Deputy General Manager since July 01, 2011. Ms. Lorentz-Poinsot has been an Executive Direct...
CEO Compensation Analysis
Compensation vs Market: Valérie's total compensation ($USD1.00M) is above average for companies of similar size in the French market ($USD746.22K).
Compensation vs Earnings: Valérie's compensation has been consistent with company performance over the past year.
|GM & Executive Director||1.83yrs||€841.10k||0.010% |
|Deputy GM||4.83yrs||€1.18m||no data|
|Administrative & Financial Director||0.83yr||no data||no data|
|Group Marketing Director||0.83yr||no data||no data|
|Sales Director||0.83yr||no data||no data|
|Deputy General Manager||no data||no data||no data|
|Group Treasurer||19yrs||no data||no data|
Experienced Management: BOI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|GM & Executive Director||1.83yrs||€841.10k||0.010% |
|Independent Director||10.5yrs||€45.63k||no data|
|Chairman of the Board of Directors||9.33yrs||€296.09k||3.4% |
|Employee Shareholder Representative Director||3.5yrs||€57.98k||no data|
|Employee Representative Director||2.42yrs||€92.44k||no data|
Experienced Board: BOI's board of directors are seasoned and experienced ( 10.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Boiron SA's company bio, employee growth, exchange listings and data sources
- Name: Boiron SA
- Ticker: BOI
- Exchange: ENXTPA
- Founded: 1932
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €674.075m
- Shares outstanding: 17.51m
- Website: https://www.boiron.com
Number of Employees
- Boiron SA
- 2, avenue de l’Ouest Lyonnais
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BOIR.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jan 1992|
|BOI||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||Jan 1992|
|BON||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jan 1992|
|0DTF||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Jan 1992|
|BOIP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Jan 1992|
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded home...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 18:51|
|End of Day Share Price||2020/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.